Joseph D. Keegan - 20 Aug 2026 Form 4 Insider Report for INTERPACE BIOSCIENCES, INC. (IDXG)

Reporting relationship: Director
Issuer ticker: IDXG
Reported as of: 20 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Aug 2026, 17:02:57 UTC
Prior SEC filing: 03 Nov 2025
Next SEC filing: 02 Nov 2026
Source filing: View source filing
Reporting owner signature: /s/ JOSEPH D KEEGAN

Filing notes and source

Key filing fact

Joseph D. Keegan filed Form 4 for INTERPACE BIOSCIENCES, INC. (IDXG) on 20 Aug 2026.

Key facts

This page summarizes Joseph D. Keegan's Form 4 filing for INTERPACE BIOSCIENCES, INC. (IDXG).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Aug 2026, 17:02.

Change

Previous filing in this sequence was filed on 03 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001260556 Primary reporting owner

KEEGAN JOSEPH D

Relationship: Director
Address: C/O INTERPACE BIOSCIENCES, INC., 2001 ROUTE 46 WATERVIEW PLAZA, SUITE 310, PARSIPPANY
Signature: /s/ JOSEPH D KEEGAN
Signature date: 20 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXG transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +69,252
Change %
Price: $0.000000^*
Shares after: 69,252
Date: 20 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 69,252
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

Footnote F2

The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.